Evidence map›Paper›PMID 31645610›Full record

ArticleScientific reports2019

Regulatory Crosstalk of Doxorubicin, Estradiol and TNFα Combined Treatment in Breast Cancer-derived Cell Lines.

Isar Nassiri, Alberto Inga, Erna Marija Meškytė, Federica Alessandrini, Yari Ciribilli, Corrado Priami

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. iScience · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Isar NassiriDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Alberto IngaLaboratory of Transcriptional Networks, Department CIBIO, University of Trento, 38123, Trento, Italy.
Erna Marija MeškytėLaboratory of Molecular Cancer Genetics, Department CIBIO, University of Trento, 38123, Trento, Italy.
Federica AlessandriniLaboratory of Molecular Cancer Genetics, Department CIBIO, University of Trento, 38123, Trento, Italy.
Yari CiribilliLaboratory of Molecular Cancer Genetics, Department CIBIO, University of Trento, 38123, Trento, Italy.ORCID http://orcid.org/0000-0001-9231-379X
Corrado PriamiThe Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI), Rovereto, TN, Italy. priami@cosbi.eu.ORCID http://orcid.org/0000-0002-3261-6235

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a new model of ESR1 network regulation based on analysis of Doxorubicin, Estradiol, and TNFα combination treatment in MCF-7. We used Doxorubicin as a therapeutic agent, TNFα as marker and mediator of an inflammatory microenvironment and 17β-Estradiol (E2) as an agonist of Estrogen Receptors, known predisposing factor for hormone-driven breast cancer, whose pharmacological inhibition reduces the risk of breast cancer recurrence. Based on the results of transcriptomics analysis, we found 71 differentially expressed genes that are specific for the combination treatment with Doxorubicin + Estradiol + TNFα in comparison with single or double treatments. The responsiveness to the triple treatment was examined for seven genes by qPCR, of which six were validated, and then extended to four additional cell lines differing for p53 and/or ER status. The results of differential regulation enrichment analysis highlight the role of the ESR1 network that included 36 of 71 specific differentially expressed genes. We propose that the combined activation of p53 and NF-kB transcription factors significantly influences ligand-dependent, ER-driven transcriptional responses, also of the ESR1 gene itself. These results provide a model of coordinated interaction of TFs to explain the Doxorubicin, E2 and TNFα induced repression mechanisms.

Indexed as

Breast NeoplasmsCell Line, TumorDoxorubicinEstradiolEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansModels, BiologicalReproducibility of ResultsSignal TransductionTumor Necrosis Factor-alphaDoxorubicinESR1 protein, humanEstradiolEstrogen Receptor alphaTumor Necrosis Factor-alpha

Identifiers

PMID31645610
PMCPMC6811586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.